Document Detail


Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
MedLine Citation:
PMID:  17010798     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The goal of this work was to determine whether the blockade of histamine H2 receptors is beneficial for the pathophysiology of chronic heart failure (CHF). BACKGROUND: Because CHF is one of the major life-threatening diseases, we need to find a novel effective therapy. Intriguingly, our previous study, which predicts the involvement of histamine in CHF, suggests that we should test this hypothesis in patients with CHF. METHODS: We selected 159 patients who received famotidine among symptomatic CHF patients for the retrospective study. We blindly selected age- and gender-matched CHF patients receiving drugs for gastritis other than histamine H2 receptor blockers as a control group. For the prospective study, 50 symptomatic CHF patients were randomly divided into 2 groups. One group received famotidine of 30 mg/day for 6 months, and the other group received teprenone. RESULTS: In the retrospective study, famotidine of 20 to 40 mg decreased both left ventricular end-diastolic and end-systolic lengths (LVDd and LVDs, respectively) and the plasma B-type natriuretic peptide (BNP) levels (182 +/- 21 vs. 259 +/- 25 pg/ml, p < 0.05) with unaltered fractional shortening (FS). In a randomized, open-label study, compared with teprenone, famotidine of 30 mg prospectively decreased both New York Heart Association functional class (p < 0.05) and plasma BNP levels (183 +/- 26 pg/ml vs. 285 +/- 41 pg/ml, p < 0.05); this corresponded to decreasing both LVDd (57 +/- 2 mm vs. 64 +/- 2 mm, p < 0.05) and LVDs (47 +/- 2 mm vs. 55 +/- 2 mm, p < 0.05) with unaltered FS (15 +/- 1% vs. 17 +/- 1%). The frequency of readmission because of worsening of CHF was lower in the famotidine group (4% and 24%, p < 0.05). On the other hand, teprenone had no effects on CHF. CONCLUSIONS: Famotidine improved both cardiac symptoms and ventricular remodeling associated with CHF. Histamine H2 receptor blockers may have therapeutic benefits for CHF.
Authors:
Jiyoong Kim; Akiko Ogai; Satoshi Nakatani; Kazuhiko Hashimura; Hideaki Kanzaki; Kazuo Komamura; Masanori Asakura; Hiroshi Asanuma; Soichiro Kitamura; Hitonobu Tomoike; Masafumi Kitakaze
Related Documents :
15882668 - Early brain natriuretic peptide increase reflects acute myocardial ischemia in patients...
12628948 - Changes in brain natriuretic peptide and norepinephrine over time and mortality and mor...
18057888 - Interventricular mechanical dyssynchrony determines abnormal heightening of plasma n-te...
18067448 - Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review.
9296398 - Continuous cardiac output monitoring during adult liver transplantation: thermal filame...
2224938 - Occlusion time dependency of regional noradrenaline release and cardiac arrhythmias dur...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-09-14
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  48     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-02     Completed Date:  2006-10-12     Revised Date:  2007-04-04    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1378-84     Citation Subset:  AIM; IM    
Affiliation:
Cardiovascular Division, National Cardiovascular Center, Suita City, Osaka Pref, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cardiac Output, Low / drug therapy*,  physiopathology*
Chronic Disease
Famotidine / therapeutic use*
Female
Gastroesophageal Reflux / drug therapy
Histamine H2 Antagonists / therapeutic use*
Humans
Male
Prospective Studies
Receptors, Histamine H2 / physiology
Retrospective Studies
Ventricular Dysfunction, Left / drug therapy
Chemical
Reg. No./Substance:
0/Histamine H2 Antagonists; 0/Receptors, Histamine H2; 76824-35-6/Famotidine
Comments/Corrections
Comment In:
J Am Coll Cardiol. 2007 Mar 13;49(10):1107; author reply 1107-8   [PMID:  17349895 ]
J Am Coll Cardiol. 2006 Oct 3;48(7):1385-6   [PMID:  17010799 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease ...
Next Document:  Increased level of pericardial insulin-like growth factor-1 in patients with left ventricular dysfun...